Form 4 for KURA Kura Oncology, Inc.
Accepted 2026-05-20 16:05:18 ET · period of report 2026-05-18 · accession 0001193125-26-232546 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-05-20 16:05 | 2026-05-18 | KURA | Bair Teresa Brophy | CLO | S - Sale | $9.38 | -2,256 | 226.9K | -1.0% | -$21.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-18 | S | D | 2,256 | $9.38 | 226,931 | D | — | — | (F1) The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025. (F2) 2,256 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan. (F3) This transaction was executed in multiple trades at prices ranging from $9.28 to $9.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |